Tumor Biology最新文献

筛选
英文 中文
Abstract 2831: Exosome gene signatures characterize metastatic dynamicity 摘要2831:外显子基因特征表征转移动力学
Tumor Biology Pub Date : 2021-07-01 DOI: 10.1158/1538-7445.AM2021-2831
Amber Gonda, Jay V. Shah, Jake N. Siebert, Nanxia Zhao, M. Kwon, P. Moghe, Nicola L Francis, V. Ganapathy
{"title":"Abstract 2831: Exosome gene signatures characterize metastatic dynamicity","authors":"Amber Gonda, Jay V. Shah, Jake N. Siebert, Nanxia Zhao, M. Kwon, P. Moghe, Nicola L Francis, V. Ganapathy","doi":"10.1158/1538-7445.AM2021-2831","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-2831","url":null,"abstract":"","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48345612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract LB009: Dynamic changes in the compositions of cancer associated-fibroblasts correlate with clinical outcome in breast cancer 摘要:癌症相关成纤维细胞组成的动态变化与乳腺癌的临床结局相关
Tumor Biology Pub Date : 2021-07-01 DOI: 10.1158/1538-7445.AM2021-LB009
G. Friedman, Oshrat Levi-Galibov, Eyal David, Chamutal Bornstein, Amir Giladi, M. Dadiani, A. Mayo, Coral Halperin, M. Pevsner-Fischer, H. Lavon, Shimrit Mayer, R. Nevo, Yan Stein, Nora Balint-Lahat, I. Barshack, H. R. Ali, C. Caldas, E. Gal-Yam, U. Alon, I. Amit, Ruth Scherz-Shouval
{"title":"Abstract LB009: Dynamic changes in the compositions of cancer associated-fibroblasts correlate with clinical outcome in breast cancer","authors":"G. Friedman, Oshrat Levi-Galibov, Eyal David, Chamutal Bornstein, Amir Giladi, M. Dadiani, A. Mayo, Coral Halperin, M. Pevsner-Fischer, H. Lavon, Shimrit Mayer, R. Nevo, Yan Stein, Nora Balint-Lahat, I. Barshack, H. R. Ali, C. Caldas, E. Gal-Yam, U. Alon, I. Amit, Ruth Scherz-Shouval","doi":"10.1158/1538-7445.AM2021-LB009","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-LB009","url":null,"abstract":"Cancer associated fibroblasts (CAFs) are prevalent in carcinomas. CAFs are also heterogeneous and perform various tumor-promoting tasks. Understanding whether distinct CAF-subsets exert specific functions, and how the composition of CAFs changes as tumors evolve could improve the accuracy of cancer treatment. Here, we analyzed thousands of CAFs by single-cell RNA-sequencing and index-sorting at several timepoints along breast tumor progression in mice, revealing distinct CAF-subsets. We discovered that the transcriptional programs of these subsets change over time, shifting from an immune-regulatory program at earlier timepoints to wound-healing and antigen-presenting programs at later timepoints, indicating that the composition and functions of CAFs are dynamic. We also found the two main CAF subsets in human breast tumors, wherein their ratio was associated with disease outcome. This association was particularly correlated with BRCA mutations in triple-negative breast cancer. Our findings indicate that the diverse composition of CAFs in breast cancer changes over time as tumors progress, and that these changes are linked to disease outcome. Citation Format: Gil Friedman, Oshrat Levi-Galibov, Eyal David, Chamutal Bornstein, Amir Giladi, Maya Dadiani, Avi Mayo, Coral Halperin, Meirav Pevsner-Fischer, Hagar Lavon, Shimrit Mayer, Reinat Nevo, Yaniv Stein, Nora Balint-Lahat, Iris Barshack, H. Raza Ali, Carlos Caldas, Einav Nili Gal-Yam, Uri Alon, Ido Amit, Ruth Scherz-Shouval. Dynamic changes in the compositions of cancer associated-fibroblasts correlate with clinical outcome in breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr LB009.","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45309453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 3096: A novel ZIP4-NOTCH3-HDAC4 axis in ovarian cancer stem cells 摘要3096:卵巢癌症干细胞中新的ZIP4-NOTCH3-HDAC4轴
Tumor Biology Pub Date : 2021-07-01 DOI: 10.1158/1538-7445.AM2021-3096
Yan Xu, Qipeng Fan, R. Emerson
{"title":"Abstract 3096: A novel ZIP4-NOTCH3-HDAC4 axis in ovarian cancer stem cells","authors":"Yan Xu, Qipeng Fan, R. Emerson","doi":"10.1158/1538-7445.AM2021-3096","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-3096","url":null,"abstract":"High grade serous ovarian cancer (HGSOC) is one of the most deadly and heterogenic cancers. We have recently shown that ZIP4 (gene name SLC39A4), a zinc transporter, is a novel cancer stem cell (CSC) marker in HGSOC. 100-200 ZIP4+, but not ZIP4-, cells from both PE04 and PEA2 cells formed larger tumors than those from 100-200 ALDH+ cells in mice. Mechanistically, we found that ZIP4 was an upstream regulator of another CSC-marker, NOTCH3, in HGSOC cells. NOTCH3 was functionally involved in spheroid formation in vitro and tumorigenesis in vivo in HGSOC. Drug-resistance is one of the main characteristics of CSCs, While ZIP4 converts drug-resistance to cisplatin (CDDP) and doxorubicin (DOX) as we reported previously, we unexpectedly found that ZIP4 induced a sensitization of HGSOC cells to histone deacetylase inhibitors (HDACis). In particular, only those HDACis against the Class IIa HDACs showed ZIP4-dependent sensitization. ZIP4 selectively up-regulated HDAC IIa HDACs, including HDAC4 and 5, with little or no effects to HDACs in other classes. ZIP4 knockout (KO) and HDAC4 knockdown (KD) increased cell resistance to LMK-235, a selective HDAC4/5 inhibitor. LMK-235 and HDAC4 knockdown (KD) inhibited spheroid formation in vitro and tumor development in vivo. Collectively, we revealed a novel ZIP4-NOTCH3-HDAC4 axis, which is functionally involved and important in CSC-related activities in vitro and tumorigenesis in vivo, and provide an innovative targeting strategy to CSC. Citation Format: Yan Xu, Qipeng Fan, Robert Emerson. A novel ZIP4-NOTCH3-HDAC4 axis in ovarian cancer stem cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 3096.","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45914469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 3176: Inhibitory activity of Globo-H and SSEA-4 on activated T-cells 3176: Globo-H和SSEA-4对活化t细胞的抑制作用
Tumor Biology Pub Date : 2021-07-01 DOI: 10.1158/1538-7445.AM2021-3176
Tzer-Min Kuo, Chin-Chan Lee, J. Lai, C. Su, M. Lai
{"title":"Abstract 3176: Inhibitory activity of Globo-H and SSEA-4 on activated T-cells","authors":"Tzer-Min Kuo, Chin-Chan Lee, J. Lai, C. Su, M. Lai","doi":"10.1158/1538-7445.AM2021-3176","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-3176","url":null,"abstract":"","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46261848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract LB250: Development of organoid raft cultures of cervical, breast and glioblastoma tumors as quick economical ex vivo human cancer models for pre-clinical drug evaluation LB250:宫颈、乳腺和胶质母细胞瘤类器官筏培养的发展作为快速经济的离体人类癌症模型,用于临床前药物评估
Tumor Biology Pub Date : 2021-07-01 DOI: 10.1158/1538-7445.AM2021-LB250
N. Banerjee, Dianne W. Moore, Abhisek Gangrade, D. Buchsbaum, L. Nabors, T. Broker, L. Chow
{"title":"Abstract LB250: Development of organoid raft cultures of cervical, breast and glioblastoma tumors as quick economical ex vivo human cancer models for pre-clinical drug evaluation","authors":"N. Banerjee, Dianne W. Moore, Abhisek Gangrade, D. Buchsbaum, L. Nabors, T. Broker, L. Chow","doi":"10.1158/1538-7445.AM2021-LB250","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-LB250","url":null,"abstract":"Background: In the past few years, 3D organoid cultures of patient-derived tumors or patient-derived xenografts have gained significant attention as faster and more economical ex vivo alternatives to animal models for the pre-clinical evaluation of therapeutics. We reported previously that raft cultures of ex vivo epithelial warts, normal human epithelia from various anatomic sites, as well as cancer cell lines (cervical and melanoma) grown at the liquid:air interface recapitulate parental tissue phenotypes. Here we describe adaptation of the above technique to develop Organoid Raft Culture (ORC) of tumors of various origin and validation as preclinical models for drug evaluation. Methods: A stromal equivalent (SE) consisting of buffered rat-tail collagen and J2 mouse fibroblasts was prepared in 24-well tissue culture plates. Freshly harvested tumors from patients or patient-derived xenografts of cervical cancers were minced to Citation Format: Nilam Sanjib Banerjee, Dianne W. Moore, Abhisek Gangrade, Donald J. Buchsbaum, Luise Burt Nabors, Thomas R. Broker, Louise T. Chow. Development of organoid raft cultures of cervical, breast and glioblastoma tumors as quick economical ex vivo human cancer models for pre-clinical drug evaluation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr LB250.","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46491860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 2890: Mitotic inhibitors suppresses tumor formation and metastasis of triple negative breast cancer (TNBC) 2890:有丝分裂抑制剂抑制三阴性乳腺癌(TNBC)的肿瘤形成和转移
Tumor Biology Pub Date : 2021-07-01 DOI: 10.1158/1538-7445.AM2021-2890
C. Song, SeungBaek Lee
{"title":"Abstract 2890: Mitotic inhibitors suppresses tumor formation and metastasis of triple negative breast cancer (TNBC)","authors":"C. Song, SeungBaek Lee","doi":"10.1158/1538-7445.AM2021-2890","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-2890","url":null,"abstract":"","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42463666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 3173: NetrinG1's pro-tumor role on stroma-derived extracellular vesicles in pancreatic cancer 摘要3173:NetrinG1在胰腺癌基质源性细胞外囊泡中的促肿瘤作用
Tumor Biology Pub Date : 2021-07-01 DOI: 10.1158/1538-7445.am2021-3173
K. Raghavan, Debora Vendramini, R. Francescone, J. Franco-Barraza, E. Cukierman
{"title":"Abstract 3173: NetrinG1's pro-tumor role on stroma-derived extracellular vesicles in pancreatic cancer","authors":"K. Raghavan, Debora Vendramini, R. Francescone, J. Franco-Barraza, E. Cukierman","doi":"10.1158/1538-7445.am2021-3173","DOIUrl":"https://doi.org/10.1158/1538-7445.am2021-3173","url":null,"abstract":"","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42471343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 2753: Deciphering macrophage function in lung tumor microenvironment and disease progression 摘要:巨噬细胞在肺肿瘤微环境和疾病进展中的功能解读
Tumor Biology Pub Date : 2021-07-01 DOI: 10.1158/1538-7445.AM2021-2753
Elizabeth A. Yu, Wei Wu, Philippe Gui, C. McCoach, C. Blakely, S. Christenson, T. Bivona
{"title":"Abstract 2753: Deciphering macrophage function in lung tumor microenvironment and disease progression","authors":"Elizabeth A. Yu, Wei Wu, Philippe Gui, C. McCoach, C. Blakely, S. Christenson, T. Bivona","doi":"10.1158/1538-7445.AM2021-2753","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-2753","url":null,"abstract":"","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42856942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 2666: HMGA1: An epigenetic switch required for MPN progression by inducingGATA-2and cell cycle progression through enhancer rewiring 摘要2666:HMGA1:通过诱导GATA-2进行MPN进展和通过增强子重组进行细胞周期进展所需的表观遗传学开关
Tumor Biology Pub Date : 2021-07-01 DOI: 10.1158/1538-7445.AM2021-2666
Liping Li, Jung Hyun Kim, Wenyan Lu, Donna M. Williams, L. Xian, Joseph Kim, O. Rogers, R. Rampal, R. Koche, L. Cope, K. Reddy, D. Matson, Joe Zhao, J. Spivak, A. Moliterno, L. Resar
{"title":"Abstract 2666: HMGA1: An epigenetic switch required for MPN progression by inducingGATA-2and cell cycle progression through enhancer rewiring","authors":"Liping Li, Jung Hyun Kim, Wenyan Lu, Donna M. Williams, L. Xian, Joseph Kim, O. Rogers, R. Rampal, R. Koche, L. Cope, K. Reddy, D. Matson, Joe Zhao, J. Spivak, A. Moliterno, L. Resar","doi":"10.1158/1538-7445.AM2021-2666","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-2666","url":null,"abstract":"","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48035259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 3143: Monitoring circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) genomic alterations in ER positive (POS)/HER2 negative (NEG) advanced breast cancer during endocrine therapy: correlative study of AZD9496 oral SERD phase I trial 3143:监测ER阳性(POS)/HER2阴性(NEG)晚期乳腺癌内分泌治疗期间循环肿瘤细胞(CTC)和循环肿瘤DNA (ctDNA)基因组改变:AZD9496口服SERD I期试验的相关研究
Tumor Biology Pub Date : 2021-07-01 DOI: 10.1158/1538-7445.AM2021-3143
A. Cani, Emily M Dolce, Elizabeth P. Darga, K. Hu, Martha E. Brown, C. Liu, J. Pierce, K. Bradbury, K. Aung, G. Schiavon, Danielle Carroll, T. Carr, T. Klinowska, J. Lindemann, G. Marshall, V. Rowlands, E. Harrington, J. Barrett, A. Armstrong, R. Baird, E. Hamilton, S. Im, K. Jhaveri, M. Patel, C. Dive, S. Tomlins, A. Udager, D. Hayes, C. Paoletti
{"title":"Abstract 3143: Monitoring circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) genomic alterations in ER positive (POS)/HER2 negative (NEG) advanced breast cancer during endocrine therapy: correlative study of AZD9496 oral SERD phase I trial","authors":"A. Cani, Emily M Dolce, Elizabeth P. Darga, K. Hu, Martha E. Brown, C. Liu, J. Pierce, K. Bradbury, K. Aung, G. Schiavon, Danielle Carroll, T. Carr, T. Klinowska, J. Lindemann, G. Marshall, V. Rowlands, E. Harrington, J. Barrett, A. Armstrong, R. Baird, E. Hamilton, S. Im, K. Jhaveri, M. Patel, C. Dive, S. Tomlins, A. Udager, D. Hayes, C. Paoletti","doi":"10.1158/1538-7445.AM2021-3143","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-3143","url":null,"abstract":"Purpose: The vast majority of advanced ER POS breast cancers eventually cease responding to endocrine (ET) and other therapies leading to evolution of lethal disease. However, timely monitoring of the molecular events associated with response/progression in tissue biopsies is logistically difficult. The use of liquid biopsies, such as CTC and ctDNA, in this context has been of recent interest. Patients and Methods: Individual CTC and ctDNA were obtained at different time points from patients with advanced ER POS/HER2 NEG breast cancer enrolled in a Phase I trial of AZD9496, an oral selective estrogen receptor degrader (SERD) ET. The CTC, purified using tandem CellSearch®/DepArray™ technologies, were genomically profiled by DNA single cell next generation sequencing (scNGS). Plasma ctDNA was isolated from blood collected in Streck BCT tubes. Genomic profiling was performed by targeted gene panel scNGS for CTC and ddPCR for ERα gene (ESR1) mutations in ctDNA. Results: 123 high-quality CTCs from 12 patients profiled by scNGS showed 100% concordance with ctDNA in detection of driver ESR1 somatic mutations. CTC scNGS additionally revealed extensive intra-patient heterogeneity of driver alterations, that would have been unresolvable by bulk ctDNA profiling, including separate subclonal CTC populations emerging within the same patient. ScNGS revealed potential opportunities for targeted therapies in 73% of patients, directed at alterations in PIK3CA, FGFR2, KIT and BRAF, at times present as 2 or more targets in the same or different cell populations. In one patient, an emergent, distinct, BRAF p.V600E targetable alteration was detected in a subpopulation of CTCs collected at the progression time point but not at baseline. Conclusion: Serial monitoring of CTC and ctDNA genomic alterations is feasible and should enable real-time tracking of response/progression, tumor evolution and opportunities for precision medicine interventions. Citation Format: Andi K. Cani, Emily M. Dolce, Elizabeth P. Darga, Kevin Hu, Martha Brown, Chia-Jen Liu, Jackie Pierce, Kieran Bradbury, Kimberly Aung, Gaia Schiavon, Danielle Carroll, T. H. Carr, Teresa Klinowska, Justin Lindemann, Gayle Marshall, Vicky Rowlands, Elizabeth A. Harrington, J. Barrett, Anne Armstrong, Richard Baird, Erika Hamilton, Seock-Ah Im, Komal Jhaveri, Manish R. Patel, Caroline Dive, Scott A. Tomlins, Aaron M. Udager, Daniel F. Hayes, Costanza Paoletti. Monitoring circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) genomic alterations in ER positive (POS)/HER2 negative (NEG) advanced breast cancer during endocrine therapy: correlative study of AZD9496 oral SERD phase I trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 3143.","PeriodicalId":23364,"journal":{"name":"Tumor Biology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48148360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信